TrialInternational journal of hematology2024

Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.

Takanori Teshima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.